124 related articles for article (PubMed ID: 35963522)
1. Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq).
Gricourt G; Tran Quang V; Cayuela JM; Boudali E; Tarfi S; Barathon Q; Daveau R; Joy C; Wagner-Ballon O; Bories D; Pautas C; Maury S; Rea D; Roy L; Sloma I
J Mol Diagn; 2022 Nov; 24(11):1113-1127. PubMed ID: 35963522
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
4. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
5. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.
Linhartova J; Hovorkova L; Soverini S; Benesova A; Jaruskova M; Klamova H; Zuna J; Machova Polakova K
Mol Cancer; 2015 Apr; 14():89. PubMed ID: 25928096
[TBL] [Abstract][Full Text] [Related]
7. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
Romzova M; Smitalova D; Tom N; Jurcek T; Culen M; Zackova D; Mayer J; Racil Z
Br J Haematol; 2020 May; 189(3):469-474. PubMed ID: 32037516
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.
Dey S; Basu S; Shah S; Bhattacharyya D; Gupta PP; Acharjee M; Roychoudhury S; Nath S
Cancer Treat Res Commun; 2022; 33():100635. PubMed ID: 36155130
[TBL] [Abstract][Full Text] [Related]
9. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
10. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.
Kastner R; Zopf A; Preuner S; Pröll J; Niklas N; Foskett P; Valent P; Lion T; Gabriel C
Eur J Cancer; 2014 Mar; 50(4):793-800. PubMed ID: 24365090
[TBL] [Abstract][Full Text] [Related]
11. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
12. Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
Kim B; Lee H; Shin S; Lee ST; Choi JR
J Mol Diagn; 2019 Jan; 21(1):163-170. PubMed ID: 30347268
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.
Minervini CF; Cumbo C; Orsini P; Anelli L; Zagaria A; Impera L; Coccaro N; Brunetti C; Minervini A; Casieri P; Tota G; Russo Rossi A; Specchia G; Albano F
Exp Mol Pathol; 2017 Aug; 103(1):33-37. PubMed ID: 28663031
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Soverini S; Bavaro L; De Benedittis C; Martelli M; Iurlo A; Orofino N; Sica S; Sorà F; Lunghi F; Ciceri F; Galimberti S; Baratè C; Bonifacio M; Scaffidi L; Castagnetti F; Gugliotta G; Albano F; Russo Rossi AV; Stagno F; di Raimondo F; D'Adda M; di Bona E; Abruzzese E; Binotto G; Sancetta R; Salvucci M; Capodanno I; Girasoli M; Coluzzi S; Attolico I; Musolino C; Calistri E; Annunziata M; Bocchia M; Stella S; Serra A; Errichiello S; Saglio G; Pane F; Vigneri P; Mignone F; Laginestra MA; Pileri SA; Percesepe A; Tenti E; Rosti G; Baccarani M; Cavo M; Martinelli G
Blood; 2020 Feb; 135(8):534-541. PubMed ID: 31877211
[TBL] [Abstract][Full Text] [Related]
15. Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm.
Frederick L; Beardell F; Viswanatha DS
Hum Pathol; 2014 Aug; 45(8):1784-9. PubMed ID: 24927924
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.
Alikian M; Ellery P; Forbes M; Gerrard G; Kasperaviciute D; Sosinsky A; Mueller M; Whale AS; Milojkovic D; Apperley J; Huggett JF; Foroni L; Reid AG
J Mol Diagn; 2016 Mar; 18(2):176-89. PubMed ID: 26857065
[TBL] [Abstract][Full Text] [Related]
17. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
[TBL] [Abstract][Full Text] [Related]
19. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
20. Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia.
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Kearney HM; Greipp PT; Hoppman NL; Baughn LB; Ketterling RP
Hum Pathol; 2019 Jul; 89():109-114. PubMed ID: 30267776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]